More recently, iBETs have shown beneficial responses in a wide range of inflammatory diseases [11], mainly through the modulation of the NF-κB pathway and blocking downstream proinflammatory-related gene expression [12], as well as the inhibition of the Th17/IL17 immune response [42,43], as we have previously described in different models of experimental kidney diseases, including the NTS nephritis model [32]. This evidence concerns the gene NFKB1 and kidney disorder.